Navigation Links
Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Date:2/23/2011

CARLSBAD, Calif., Feb. 23, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein (CRP) in the cohort of subjects in the study with elevated CRP.  In this study, ISIS-CRPRx was well tolerated at doses up to 600 mg/week.  Isis plans to evaluate ISIS-CRPRx in Phase 2 studies in indications that could provide early proof-of-concept in diseases with elevated CRP.  Isis plans to initially evaluate ISIS-CRPRx in multiple myeloma and rheumatoid arthritis, before expanding into cardiovascular and other diseases.  

"CRP levels are increased in many inflammatory disorders, and excessive amounts of CRP have been linked to multiple clinical conditions, including cardiovascular disease and diabetes," said Paul M. Ridker, M.D., Eugene Braunwald Professor of Medicine at the Brigham and Women's Hospital and Harvard Medical School.  "This is the first evaluation of a selective CRP inhibitor and the first such drug shown to be active in man. What this new agent thus provides is a method to directly test whether or not lowering CRP per se might be beneficial for patient care, something that could not be addressed in the past."

The Phase 1 study of ISIS-CRPRx was a blinded, randomized, placebo-controlled, dose-escalation study designed to assess the safety and pharmacokinetic profile of ISIS-CRPRx as well as to assess the initial effects of the drug on baseline CRP levels.  ISIS-CRPRx was evaluated in single and multiple doses ranging from 50 mg per week to 600 mg per week in 80 healthy volunteers.  In all but one cohort, Isis enrolled subjects who had normal (generally undetectable to less than 2 mg/L) CRP levels.  In the 600 mg per week multi-dose cohort, Isis enrolled eight subjec
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... and Chinese Medical X-ray Film Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese Medical X-Ray ... study on the current state of the Global medical ... situation. The report provides a basic overview of ...
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
(Date:7/12/2014)... July 12, 2014 Ladies, it doesn't matter ... there. Those who are looking for an affordable gown can ... special occasion dresses) to get their dream items. Recently, the ... tea length gowns . Along with that, it is also ... enjoy the special offer; the deadline of this promotion is ...
(Date:7/11/2014)... July 12, 2014 According to ... total market is expected to register a CAGR ... , Browse 71 market data tables and 76 ... on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market ...
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- Reducing the ... incidence of Lyme disease and other tick-borne infections ... that deer populations can be manipulated to reduce human ... of contracting Lyme disease," the researchers wrote. White-tailed ... which transmit Lyme disease to people. The study ...
(Date:7/11/2014)... UK (PRWEB) July 11, 2014 Microbiology ... of the in-vitro diagnostics industry, which is expected to ... ten years. The sector owes its growth to the ... to people’s health worldwide and a major factor leading ... technologies, threat of bio-terrorism, and a broader availability of ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Datalogic brings ... in improving sanitation hospital wide. With their new ... spread of disease, like the devastating MRSA, which claimed ... Gryphon GD4400-HC 2D and the Gryphon GM4400-HC ... barcodes and can even read barcodes off of troublesome ...
Breaking Medicine News(10 mins):Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3
... earthbound "angels" who have,brightened the lives of Michigan children ... The Caring for Children Angel Awards recognize good ... awards have been,sponsored annually by the Michigan Blues since ... a Friday, Nov. 9 reception and awards,program at the ...
... to remove,some fat (cellulite) and also tighten your skin ... Plastic Surgery and Laser Center in Farmington Hills,offers a ... goals -- without surgery. What,s more they can ... Farmington Hills plastic surgeon and,owner of the Center, said ...
... (NMA) announced the appointment of Byron Sogie-Thomas, M.S., ... Policy, Mr. Sogie-Thomas,will be responsible for advising the ... current policy issues. He will also assume overall,responsibility ... federal law,regulation, and policy. "Byron,s knowledge of ...
... Pharmacists Association (NCPA) is pleased today to announce ... public affairs., "We,re pleased to have such ... team," said Bruce Roberts, RPh, NCPA Executive Vice,President ... and,Administration experience will undoubtedly increase our organization,s,volume as ...
... for Hospital Quality,Improvement, BALTIMORE, Oct. 11 ... the mid-Atlantic region were,recently honored with a ... America. CareFirst BlueCross BlueShield (CareFirst) received,the 2007 ... 100,000 Lives and,Beyond Collaborative. CareFirst and the ...
... by diabetes to enter global,contest supporting children in developing nations and ... ... 11 "American Idol" finalist and,rising Hickory Records recording artist Elliott ... the Inspired by Diabetes global,campaign to support the care of children ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 3Health News:Prominent Farmington Plastic Surgeon Uses Two New Non-Surgical Procedures to Tighten Skin and Remove Fat 2Health News:National Medical Association Selects New Director of Health Policy 2Health News:Lisa Camooso Miller Joins National Community Pharmacists as Vice President of Public Affairs 2Health News:National Award Recognizes Delmarva Foundation and CareFirst BlueCross BlueShield Quality Improvement Efforts 2Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 2Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 3Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 4Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 5
... includes three major components: Blood pump, Cannulae, ... Driver. This system provides partial or total ... conventional therapy, is unable to maintain adequate ... support, blood flows from the natural heart ...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
... catheter is inserted into the subclavian or ... vena cava. The Cool Line incorporates ... temperature-controlled saline flowing within a closed-loop design, ... circulation. The Cool Line combines two ...
... The Fortius catheter provides maximum ... to target temperature. The Fortius catheter ... design to provide the ultimate solution ... catheter is inserted percutaneously into the ...
Medicine Products: